The global intravenous (IV) ibuprofen market size reached US$ 6.3 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 10.2 Billion by 2028, exhibiting agrowth rate (CAGR) of 7.78% during 2023-2028.
Ibuprofen belongs to the nonsteroidal anti-inflammatory drug (NSAID) class used to treat inflammation, pain, and fever. It inhibits cyclooxygenase COZ-1 and COX-2 enzymes that are required for the synthesis of prostaglandins (PG). Intravenous (IV) ibuprofen is used alone or with other medicines to relieve mild to severe discomfort. It is injected directly into the vein to block the body's production of certain natural substances that cause inflammation. It helps to reduce narcotic analgesic requirements and lower pain levels with an excellent safety profile. IV ibuprofen also aids in improving pain control and reducing the usage of opioid drugs in orthopedic and abdominal surgeries and fever.
Intravenous (IV) Ibuprofen Market Trends:
The steadily rising geriatric population and the increasing prevalence of arthritis, cardiovascular diseases (CVDs), and cancer across the globe are creating a positive outlook for the market. In line with this, the widespread product adoption to manage and treat inflammatory diseases, rheumatoid disorders, mild to moderate pain, fever, dysmenorrhea, and osteoarthritis is favoring the market growth. Moreover, hectic working schedules and unhealthy lifestyles, along with a consequent decline in physical activity and proper nutrition, have led to a rise in the incidences of chronic diseases, which is acting as another growth-inducing factor. Apart from this, the increasing product utilization to treat mild fever, dental pain, gastrointestinal pain, and ductus arteriosus in pediatrics is providing an impetus to the market growth. Moreover, IV ibuprofen is employed to relieve muscle or rheumatic pain, backache, neuralgia, sprains, strains, sports injuries, and musculoskeletal diseases, which is facilitating the market growth. Furthermore, the increasing demand for IV ibuprofen in orthopedic patients post knee or hip replacement surgeries to reduce pain and morphine use is positively influencing the market growth. Other factors, including significant improvements in the healthcare infrastructure, growing health consciousness among individuals, and the rising expenditure capacities of consumers, are anticipated to drive the market growth.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global intravenous (IV) ibuprofenmarket report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on product dose, indication and age group.
Breakup by Product Dose:
100 Mg Dose
200 Mg Dose
400 Mg Dose
800 Mg Dose
Breakup by Indication:
Breakup by Age Group:
Breakup by Region:
Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being Cumberland Pharmaceuticals Inc., Hyloris Pharmaceuticals SA, Recordati Rare Diseases Inc., VALMOR Laboratories CA and Xgen Pharmaceuticals Djb Inc.
Base Year of the Analysis
Product Dose, Indication, Age Group, Region
Asia Pacific, Europe, North America, Latin America, Middle East and Africa
United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Cumberland Pharmaceuticals Inc., Hyloris Pharmaceuticals SA, Recordati Rare Diseases Inc., VALMOR Laboratories CA and Xgen Pharmaceuticals Djb Inc.
10% Free Customization
Report Price and Purchase Option
Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
Post-Sale Analyst Support
PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)
Key Questions Answered in This Report
The global Intravenous (IV) ibuprofen market was valued at US$ 6.3 Billion in 2022.
We expect the global Intravenous (IV) ibuprofen market to exhibit a CAGR of 7.78% during 2023-2028.
The rising prevalence of arthritis, cancer, rheumatoid disorders, etc., along with the growing adoption of IV ibuprofen, as it assists in improving pain control and reducing the usage of opioid drugs in orthopedic and abdominal surgeries, is primarily driving the global Intravenous (IV) ibuprofen market.
The sudden outbreak of the COVID-19 pandemic has led to the increasing demand for Intravenous (IV) ibuprofen to relieve several symptoms of coronavirus infection, such as inflammation, pain, fever, etc.
Based on the indication, the global Intravenous (IV) ibuprofen market has been segregated into pain/inflammatory and fever, where pain/inflammatory currently exhibits a clear dominance in the market.
Based on the age group, the global Intravenous (IV) ibuprofen market can be bifurcated into pediatrics and adults. Currently, adults hold the largest market share.
On a regional level, the market has been classified into North America, Asia-Pacific, Europe, Latin America, and Middle East and Africa, where North America currently dominates the global market.
Some of the major players in the global Intravenous (IV) ibuprofen market include Cumberland Pharmaceuticals Inc., Hyloris Pharmaceuticals SA, Recordati Rare Diseases Inc., VALMOR Laboratories CA, and Xgen Pharmaceuticals Djb Inc.
Need more help?
Speak to our experienced analysts for insights on the current market scenarios.
Include additional segments and countries to customize the report as per your requirement.
Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
For further assistance, please connect with our analysts.
Gain a deeper dive into a specific application, geography, customer, or competitor
Any level of personalization
Get in Touch With Us
IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.
The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required
We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra
The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.
I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.
We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.